Aktienanalyse zu NeOnc Technologies Holdings Inc (NTHI)NTHINeOnc Technologies Holdings Inc

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others). It operates in the Healthcare sector.

Neonc Technologies Holdings, Inc. is a good buy right now, trading at $3.07, with a recent positive price movement of +8.87% over the last five days. The company has raised $15 million in funding, which reflects market confidence in its growth potential, particularly with its clinical trials for NEO100 and NEO212. However, the main risk is the company's significant net losses, with a net income of -14,240,044 USD reported for Q2 2026, indicating ongoing financial challenges that investors should consider.